Pharmacotherapies for cannabis dependence

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 1, 2019, Pages

  Nielsen, Suzanne ^a   Gowing, Linda ^b   Sabioni, Pamela ^c   Le Foll, Bernard ^c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ATOMOXETINE; BUSPIRONE; DRONABINOL; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; LITHIUM; LOFEXIDINE; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; OXYTOCIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VENLAFAXINE; ANTIDEPRESSANT AGENT; SEROTONIN AGONIST;

ADVERSE OUTCOME; CANNABIS ADDICTION; CLINICAL OUTCOME; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG WITHDRAWAL; HUMAN; LOW RISK POPULATION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADULT; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ACETYLCYSTEINE; ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BUSPIRONE; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 85012080119     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008940.pub3     Document Type: Review

References (141)

1. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014;71(3):281-91. [DOI: 10.1001/jamapsychiatry.2013.3947]9917975
2. Bruno R, Allsop DJ, Copeland J, McGregor L, Norberg MM, Dunlop AJ, et al. The impact of Sativex (R) on cognitive function during treatment for cannabis withdrawal. Drug and Alcohol Review 2013;32:27. 9917976
3. Kevin RC, Allsop DJ, Lintzeris N, Dunlop AJ, Booth J, McGregor IS. Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal. Forensic Toxicology 2017;35(1):33-44. 9917977
4. Montebello M, Allsop D, Copeland J, Lintzeris N, Dunlop A, Sadler C, et al. Cannabinoid replacement therapy for management of cannabis withdrawal: a randomized controlled trial of nabiximols (Sativex®). Australian and New Zealand Journal of Psychiatry 2014;48(Suppl 1):79. 9917978
5. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. American Journal on Addictions 2009;18(1):53-64. [DOI: 10.1080/10550490802408936]2860552
6. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug and Alcohol Dependence 2010;112(1-2):39-45. [DOI: 10.1016/j.drugalcdep.2010.05.010]9917979
7. Cornelius JR, Salloum IM, Ferrell R, Douaihy AB, Hayes J, Kirisci L, et al. Treatment trial and long-term follow-up evaluation among co-morbid youth with major depression and a cannabis use disorder. Advances in Psychology Research 2012;93:109-21. 9917980
8. Frewen A, Montebello ME, Baillie A, Rea F. Effects of mirtazapine on withdrawal from dependent cannabis use. 69th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2007 June 16-21; Quebec City, Canada. 2007:21. [MEDLINE: FREWEN2007]2860556
9. Frewen AR. An Examination of Withdrawal Symptoms and their Relationship with Outcomes in a Combined Behavioural and Pharmacological Intervention for Dependent Cannabis Users [thesis]. North Ryde (Australia): Macquarie University, 2009. 2860557
10. Bentzley JP, Tomko RL, Gray KM. Low pretreatment impulsivity and high medication adherence increase the odds of abstinence in a trial of N-acetylcysteine in adolescents with cannabis use disorder. Journal of Substance Abuse Treatment 2016;63:72-7. [DOI: 10.1016/j.jsat2015.12.003]9917981
11. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. American Journal of Psychiatry 2012;169(8):805-12. [DOI: 10.1176/appi.ajp.2012.12010055; EMBASE: AN 2012469181]9917982
12. McClure EA, Baker NL, Gray KM. Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. American Journal of Drug and Alcohol Abuse 2014;40(4):285-91. [DOI: 10.3109/00952990.2013.878718]9917983
13. Roten A, Baker NL, Gray KM. Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addictive Behaviors 2015;45:119-23. [DOI: 10.1016/j.addbeh.2015.01.013]9917984
14. Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addictive Behaviors 2013;38(3):1788-91. [DOI: 10.1016/j.addbeh.2012.11.003]9917985
15. Squeglia L, Baker N, McClure E, Gray K. Alcohol use during an N-acetylcysteine cannabis cessation trial in adolescents. Drug and Alcohol Dependence 2017;171:e195. [DOI: 10.1016/j.drugalcdep.2016.08.533]9917986
16. Squeglia LM, Baker NL, McClure EA, Tomko RL, Adisetiyo V, Gray KM. Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addictive Behaviors 2016;63:172-7. [DOI: 10.1016/j.addbeh.2016.08.001]9917987
17. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence 2017;177:249-57. [DOI: 10.1016/j.drugalcdep.2017.04.020]9917989
18. McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, et al. Achieving Cannabis Cessation - Evaluating N-acetylcysteine Treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemporary Clinical Trials 2014;39(2):211-23. [DOI: dx.doi.org/10.1016/j.cct.2014.08.011]9917990
19. Sherman BJ, McRae-Clark AL, Baker NL, Sonne SC, Killeen TK, Cloud K, et al. Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the Achieving Cannabis Cessation - Evaluating N-acetylcysteine Treatment (ACCENT) study. American Journal on Addictions 2017;26(2):136-44. [DOI: 10.1111/ajad.12503]9917991
20. Squeglia L, Tomko R, Baker N, McClure E, Book G, Gray K. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug and Alcohol Dependence 2018;185:17-22. [DOI: 10.1016/j.drugalcdep.2017.12.005]9917992
21. Allsop DJ, Bartlett DJ, Johnston J, Helliwell D, Winstock A, McGregor IS, et al. The effects of lithium carbonate supplemented with nitrazepam on sleep disturbance during cannabis abstinence. Journal of Clinical Sleep Medicine 2015;11(10):1153-62. [DOI: dx.doi.org/10.5664/jcsm.5090]9917994
22. Johnston J, Lintzeris N, Allsop DJ, Suraev A, Booth J, Carson DS, et al. Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology 2014;231(24):4623-36. [DOI: dx.doi.org/10.1007/s00213-014-3611-5]9917995
23. Johnston J, Lintzeris N, McGregor I, Allsop DJ, Helliwell D, Winstock A. A double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal [conference abstract]. Drug and Alcohol Review 2013;32:43. 9917996
24. Johnston J, Lintzeris N, McGregor I, Guastella A, Allsop D, Helliwell D, et al. Preliminary findings from a double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal [conference abstract]. Drug and Alcohol Review 2012;31:45. 9917997
25. Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. American Journal on Addictions 2004;13:21-32. [DOI: 10.1080/10550490490265280]2860564
26. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2011;116:142-50. [DOI: 10.1016/j.drugalcdep.2010.12.010; MEDLINE: AN 21310551]2860566
27. Kelly MA, Pavlicova M, Glass A, Mariani JJ, Bisaga A, Sullivan MA, et al. Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. Drug and Alcohol Dependence 2014;144:42-6. [DOI: 10.1016/j.drugalcdep.2014.06.040]9917998
28. Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 2013;108(6):1084-94. [DOI: 10.1111/add.12108]2860568
29. Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, et al. Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 2016;159:53-60. [DOI: 10.1016/j.drugalcdep.2015.11.025]9918000
30. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012;37:1689-98. [DOI: 10.1038/npp.2012.14]2860570
31. McRae-Clark AL, Baker NL, Sonne SC, DeVane C, Wagner A, Norton J. Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence. Journal of Substance Abuse Treatment 2015;57:70-4. [DOI: 10.1016/j.jsat.2015.05.002]9918001
32. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, et al. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug and Alcohol Dependence 2009;105:132-8. [DOI: 10.1016/j.drugalcdep.2009.06.022]2860572
33. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. American Journal on Addictions 2010;19(6):481-9. [DOI: 10.1111/j.1521-0391.2010.00076.x]2860574
34. McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, et al. Buspirone treatment of cannabis dependence: a randomized, placebo-controlled trial. Drug and Alcohol Dependence 2015;156:29-37. [DOI: 10.1016/j.drugalcdep.2015.08.013]9918003
35. Sherman BJ, Baker NL, McRae-Clark AL. Gender differences in cannabis use disorder treatment: change readiness and taking steps predict worse cannabis outcomes for women. Addictive Behaviors 2016;60:197-202. [DOI: 10.1016/j.addbeh.2016.04.014]9918004
36. McRae-Clark AL, Baker NL, Gray KM, Killeen T, Hartwell KJ, Simonian SJ. Vilazodone for cannabis dependence: a randomized, controlled pilot trial. American Journal on Addictions 2016;25(1):69-75. [DOI: 10.1111/ajad.12324]9918006
37. Gray JC, Treloar Padovano H, Wemm SE, Miranda R. Predictors of topiramate tolerability in heavy cannabis-using adolescents and young adults: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2018;38(2):134-7. [DOI: 10.1097/JCP.0000000000000843]9918008
38. Miranda R, Treloar H, Blanchard A, Justus A, Monti PM, Chun T, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addiction Biology 2017;22(3):779-90. [DOI: 10.1111/adb.12350]9918009
39. Treloar H, Blanchard A, Justus A, Monti P, Chun T, Swift R, et al. Effects of topiramate on cannabis use among youth: an initial proof-of concept trial in the natural environment. Alcoholism: Clinical and Experimental Research 2015;39:265A. 9918010
40. Penetar DM, Looby AR, Ryan ET, Maywalt MA, Lukas SE. Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Substance Abuse: Research and Treatment 2012;6:63-71. [DOI: 0.4137/SART.S9706]2860576
41. Sherman BJ, Baker NL, McRae-Clark AL. Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Research 2017;249:318-20. [DOI: 10.1016/j.psychres.2017.01.027]9918012
42. Trigo J, Soliman A, Staios G, Quilty L, Fischer B, George T, et al. Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence, a pilot study. Neuropsychopharmacology 2016;41:S422-S3. [DOI: 10.1038/npp.2016.241]9918014
43. Trigo JM, Quilty L, Soliman A, Fischer B, Rehm J, Selby P, et al. Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a pilot randomized clinical trial. Neurotherapeutics 2017;14(3):819. [DOI: 10.1007/s13311-017-0543-x]9918015
44. Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PloS One 2018;13(1):e0190768. [DOI: 10.1371/journal.pone.0190768]9918016
45. Weinstein AM, Miller H, Bluvstein I, Rapoport E, Schreiber S, Bar-Hamburger R, et al. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. American Journal of Drug and Alcohol Abuse 2014;40(1):16-22. [DOI: 10.3109/00952990.2013.819362]2860578
46. Adams TA, Arnsten JH, Ning Y, Nahvi S. Feasibility and preliminary effectiveness of varenicline for treating co-occurring cannabis and tobacco use. Journal of Psychoactive Drugs 2018;50(1):12-8. [DOI: 10.1080/02791072.2017.1370746]9918018
47. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. American Journal on Addictions 2007;16:260-8. [DOI: 10.1080/10550490701389658]2860580
48. Brown PC, Budney AJ, Thostenson JD, Stanger C. Initiation of abstinence in adolescents treated for marijuana use disorders. Journal of Substance Abuse Treatment 2013;44(4):384-90. [EMBASE: AN 2013109720]2860582
49. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug and Alcohol Dependence 2007;86(1):22-9. [CENTRAL: CN-00590656]9918020
50. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addiction Biology 2013;18(6):993-1002. [EMBASE: AN 2013769387]2860586
51. Cornelius JR, Salloum IM, Haskett RF, Ehler JG, Jarrett PJ, Thase ME, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addictive Behaviours 1999;24(1):111-4. 2860588
52. Cornelius JR, Chung T, Martin C, Wood DS, Clark DB. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addictive Behaviors 2008;33(11):1500-5. [DOI: 10.1016/j.addbeh.2008.02.001; MEDLINE: 18313860]2860590
53. Cornelius JR, Douaihy A, Daley D, Chung T, Wesesky MA, Wood DS. Mirtazapine pilot trial in comorbid MDD/SUD: long-term follow-up results. Drug and Alcohol Dependence 2015;156:e48-e9. 9918022
54. Findling RL, Pagano ME, McNamara NK, Stansbrey RJ, Faber JE, Lingler J, et al. The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial. Child and Adolescent Psychiatry and Mental Health 2009;3:11. [CENTRAL: CN-00754249; DOI: 10.1186/1753-2000-3-11]2860594
55. Hirschtritt ME, Pagano ME, Christian KM, McNamara NK, Stansbrey RJ, Lingler J, et al. Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. Journal of Substance Abuse Treatment 2012;42(4):366-72. [DOI: 10.1016/j.jsat.2011.09.010; PsycINFO AN 2011-27672-001]2860595
56. Geller B, Cooper TB, Sun K, Zimermann B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry 1998;37(2):171-8. [PsycINFO AN 1997-39092-009]2860597
57. Geller B, Cooper TB, Watts HE, Cosby CM, Fox LW. Early findings from a pharmacokinetically designed double-blind and placebo-controlled study of lithium for adolescents comorbid with bipolar and substance dependency disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1992;16(3):281-99. [EMBASE: AN 1992154297]2860598
58. Gillman MA, Harker N, Lichtigfeld FJ. Combined cannabis/methaqualone withdrawal treated with psychotropic analgesic nitrous oxide. International Journal of Neuroscience 2006;116:859-69. [CENTRAL: CN-00566721; DOI: 10.1080/00207450600753998]2860600
59. Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-Acetylcysteine (NAC) in young marijuana users: an open-label pilot study. American Journal on Addictions 2010;19(2):187-9. [DOI: 10.1111/j.1521-0391.2009.00027.x; EMBASE: 2010123976]2860602
60. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 2001;155(2):171-9. 2860604
61. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology 2003;165(2):157-65. 2860608
62. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 2003;166:77-85. [DOI: 10.1007/s00213-002-1279-8]9918024
63. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004;29:158-70. 2860610
64. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2008;197(1):157-68. 2860612
65. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2010;211(2):233-44. [CENTRAL: CN-00760900; DOI: 10.1007/s00213-010-1888-6]2860614
66. Haney M, Bedi G, Cooper Z. Nabilone dose-response in marijuana smokers: comparison to dronabinol. Neuropsychopharmacology 2010;35:S277. 9918026
67. Haney M, Bedi G, Cooper Z, Vosburg S, Comer S, Foltin R. Nabilone decreases marijuana withdrawal and relapse in the human laboratory. Neuropsychopharmacology 2011;36:S177-8. [DOI: 10.1038/npp.2011.291; EMBASE: AN 70607410]9918025
68. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 2013;38(8):1557-65. [DOI: 10.1038/npp.2013.54; MEDLINE: AN 23443718]2860617
69. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology 2015;40(11):2489-98. 9918028
70. Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug and Alcohol Dependence 2017;172:9-13. [DOI: 10.1016/j.drugalcdep.2016.11.030]9918030
71. Babalonis S, Lofwall MR, Nuzzo PA, Elayi C, Malcolm RJ, Haney M, et al. Examination of the behavioral effects of oral cannabidiol alone and in combination with smoked marijuana. Drug and Alcohol Dependence 2015;156:e13. 9918031
72. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 2016;41(8):1974-82. 9918032
73. Haney M, Cooper Z, Bedi G, Reed SC, Ramesh D, Foltin RW. Marijuana withdrawal and relapse in the human laboratory: effect of zolpidem alone and in combination with nabilone. Neuropsychopharmacology 2013;38:S508-9. [DOI: 10.1038/npp.2013.281; EMBASE: AN 71278673]9918034
74. Herrmann ES, Cooper Z, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and relapse among non-treatment-seeking cannabis users. Drug and Alcohol Dependence 2017;171:e88. [DOI: 10.1016/j.drugalcdep.2016.08.247]9918035
75. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology 2016;233(13):2469-78. 9918036
76. Nanjayya SB, Shivappa M, Chand PK, Murthy P, Benegal V. Baclofen in cannabis dependence syndrome. Biological Psychiatry 2010;68:e9-e10. [DOI: 10.1016/j.biopsych.2010.03.033; MEDLINE: 20494335]9918038
77. Notzon DP, Kelly MA, Choi CJ, Pavlicova M, Mahony AL, Brooks DJ, et al. Open-label pilot study of injectable naltrexone for cannabis dependence. American Journal of Drug and Alcohol Abuse 2018;44(6):612-29. [DOI: 10.1080/00952990.2017.1423321]9918040
78. Rubio G, Martinez I, Recio A, Ponce G, Lopez-Munoz F, Alamo C, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, crossover study. European Journal of Psychiatry 2006;20(3):133-46. 9918042
79. Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. American Journal on Addictions 2014;23(3):308-12. 9918044
80. Sevy S, Robinson DG, Sunday S, Napolitano B, Miller R, McCormack J, et al. Olanzapine vs risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Research 2011;188(3):310-4. 9918046
81. Sugarman DE, Poling J, Sofuoglu M. The safety of modafinil in combination with oral 9-tetrahydrocannabinol in humans. Pharmacology, Biochemistry and Behavior 2011;98(1):94-100. [DOI: 10.1016j.pbb.2010.12.013]2860635
82. Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug and Alcohol Dependence 2016;161:298-306. 9918048
83. Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug and Alcohol Dependence 2011;117:38-44. [DOI: 10.1016/j.drugalcdep.2011.01.003]2860639
84. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug and Alcohol Dependence 2013;128(1-2):64-70. [DOI: 10.1016/j.drugalcdep.2012.08.001; MEDLINE: AN 22921474]2860641
85. Vandrey R. Cannabis withdrawal and sleep disturbance: implications for the treatment of cannabis use disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2016;55(10):S66. 9918051
86. Vandrey R, Budney AJ, Smith M, Herrmann E, Hampson A, Stitzer ML. A pilot study of zolpidem pharmacotherapy in the treatment of cannabis use disorders. Drug and Alcohol Dependence 2015;146:e10. 9918050
87. Van Nimwegen LJ, De Haan L, Van Beveren NJ, Van Der Helm M, Van Den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Canadian Journal of Psychiatry 2008;53(6):400-5. [EMBASE: AN 2008305264]2860643
88. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. Journal of Psychopharmacology 2009;23(1):84-93. [CENTRAL: CN-00714374; DOI: 10.1177/0269881108089584]2860645
89. Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, et al. Randomised controlled trial (RCT) of cannabinoid replacement therapy (nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry 2018;18(1):140. 9918053
90. D'Souza D. FAAH inhibitor PF-04457845 in the treatment of cannabis dependence. Neuropsychopharmacology 2017;43:S72. [DOI: 10.1038/npp.2017.263]9918056
91. D'Souza D, Creatura G, Cortes-Briones J, Thurnauer H, Bluez G, Deaso E, et al. FAAH inhibitor treatment for cannabis dependence. Neuropsychopharmacology 2015;40:S437-8. 9918055
92. NCT00974376. Gabapentin treatment of cannabis dependence. clinicaltrials.gov/ct2/show/NCT00974376 (first received 1 September 2009). 9918058
93. NCT01598896. Combination of dronabinol and clonidine for cannabis dependence in patients with schizophrenia. clinicaltrials.gov/show/NCT01598896 (first received 11 May 2012). 9918060
94. NCT02044809. Cannabidiol: a novel intervention for cannabis use problems?. clinicaltrials.gov/ct2/show/NCT02044809 (first received 22 January 2014). 9918062
95. NCT02579421. Hormones and reduction in co-users of marijuana and nicotine. clinicaltrials.gov/show/NCT02579421 (first received 13 October 2015). 9918064
96. Agrawal A, Pergadia ML, Lynskey MT. Is there evidence for symptoms of cannabis withdrawal in the National Epidemiologic Survey of Alcohol and Related Conditions?. American Journal on Addictions 2008; Vol. 17, issue 3:199-208.
97. Beauvais F, Jumper-Thurman P, Helm H, Plested B, Burnside M. Surveillance of drug use among American Indian adolescents: patterns over 25 years. Journal of Adolescent Health 2004; Vol. 34, issue 6:493-500. [1054-139X]
98. Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Review of Neurotherapeutics 2008;8(3):479-91.
99. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology 2003; Vol. 112, issue 3:393-402.
100. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Current Opinion in Psychiatry 2006; Vol. 19, issue 3:233-8.
101. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addiction Science & Clinical Practice 2007; Vol. 4, issue 1:4-16.
102. Chung T, Martin CS, Cornelius JR, Clark DB. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction 2008; Vol. 103, issue 5:787-99.
103. Clough AR, D'Abbs P, Cairney S, Gray D, Maruff P, Parker R, et al. Emerging patterns of cannabis and other substance use in Aboriginal communities in Arnhem Land, Northern Territory: a study of two communities. Drug and Alcohol Review 2004; Vol. 23, issue 4:381-90.
104. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. Journal of Substance Abuse Treatment 2001; Vol. 20, issue 1:45-52.
105. Copeland J, Clement N, Swift W. Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry 2014;4(1):55-63. [DOI: 10.2217/npy.13.90]
106. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, et al. Cannabis withdrawal among non-treatment-seeking adult cannabis users. American Journal on Addictions 2006; Vol. 15, issue 1:8-14.
107. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatric Clinics of North America 2012;35(2):309-26. [DOI: 10.1016/j.psc.2012.03.003]
108. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. dsm.psychiatryonline.org 2013.
109. European Monitoring Centre for Drugs and Drug Addiction. Cannabis problems in context: understanding the increase in European treatment demands. www.emcdda.europa.eu/html.cfm/index34898EN.html 2004, issue Selected Issue 2:81-92.
110. European Monitoring Centre for Drugs and Drug Addiction. Cannabis drug profile. www.emcdda.europa.eu/publications/drug-profiles/cannabis Accessed prior to: 13 January 2019.
111. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD005336.pub4]
112. Gorelick DA. Pharmacological treatment of cannabis-related disorders: a narrative review. Current Pharmaceutical Design 2016;22(42):6409-19. [DOI: 10.2174/1381612822666160822150822]
113. Gruber AJ, Pope HG, Hudson JI, Yurgelun-Todd D. Attributes of long-term heavy cannabis users: a case-control study. Psychological Medicine 2003; Vol. 33, issue 8:1415-22.
114. Hall W, Degenhardt L, Lynskey M. The Health and Psychological Effects of Cannabis Use. 2nd Edition. Canberra (Australia): Commonwealth of Australia, 2001. [National Drug Strategy Monograph No. 44]
115. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; Vol. 374, issue 9698:1383-91.
116. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug and Alcohol Dependence 2005; Vol. 80, issue 2:147-59.
117. Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. Journal of Clinical Psychiatry 2008; Vol. 69, issue 9:1354-63.
118. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org.
119. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis. Archives of General Psychiatry 2011;68(6):555-61.
120. Lev-Ran S, Le Strat Y, Imtiaz S, Rehm J, Le Foll B. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. American Journal on Addictions 2013;22:7-13.
121. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Comprehensive Psychiatry 2013;54:589-98.
122. McCann DJ, Ramey T, Skolnick P. Outcome measures in medication trials for substance use disorders. Current Treatment Options in Psychiatry 2015;2(2):113-21.
123. McClure EA, Stitzer ML, Vandrey R. Characterizing smoking topography of cannabis in heavy users. Psychopharmacology 2012;220:309-18.
124. McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, et al. Cannabis and schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD004837.pub3]
125. Milin R, Manion I, Dare G, Walker S. Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2008; Vol. 47, issue 2:174-9.
126. Minozzi S, Davoli M, Bargagli M, Amato L, Vecchi S, Perucci C. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug and Alcohol Review 2010;29(3):304-17.
127. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. American Journal on Addictions 2007; Vol. 16:331-42.
128. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 2018;113(10):1905-26. [DOI: 10.1111/add.14234]
129. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
130. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS): 1996-2006. National Admissions to Substance Abuse Treatment Services. www.oas.samhsa.gov/copies.cfm. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2008. [DASIS Series: S-43, DHHS Publication No. (SMA) 08-4347]
131. Schubnemann H, Brozek J, Guyatt G, Oxman A, editor(s). GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 13 January 2019).
132. Sherman BJ, McRae-Clarke AL. Treatment of cannabis use disorder: current science and future outlook. Reviews of Therapeutics 2016;36(5):511-35. [DOI: 10.1002/phar.1747]
133. Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 2014;1:286-96. [DOI: 10.1016/S2215-0366(14)70307-4]
134. Silins E, Fergusson DM, Patton GC, Horwood LJ, Olsson CA, Hutchinson DM, et al. Adolescent substance use and educational attainment: an integrative data analysis comparing cannabis and alcohol from three Australasian cohorts. Drug and Alcohol Dependence 2015;156:90-6. [DOI: 10.1016/j.drugalcdep.2015.08.034]
135. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Current Drug Abuse Reviews 2008;1(1):81-98.
136. van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, Korf DJ, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 2014;109:1101-9.
137. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009; Vol. 23, issue 7:543-53.
138. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. New England Journal of Medicine 2014;370:2219-27.
139. Walther L, Gantner A, Heinz A, Majić T. Evidence-based treatment options in cannabis dependency. Deutsches Ärzteblatt International 2016;113(39):653-9. [DOI: 10.3238/arztebl.2016.0653]
140. United Nations Office on Drugs and Crime. World Drug Report 2017. www.unodc.org/wdr2017 (accessed prior to 13 January 2019). [eISBN 978-92-1-060623-3]
141. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD008940.pub2]